{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T17:15:29Z","timestamp":1773249329866,"version":"3.50.1"},"reference-count":35,"publisher":"Elsevier BV","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.dld.2013.09.001","type":"journal-article","created":{"date-parts":[[2013,9,30]],"date-time":"2013-09-30T23:04:16Z","timestamp":1380582256000},"page":"S355-S362","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"S5","title":["Optimizing treatment in HIV\/HCV coinfection"],"prefix":"10.1016","volume":"45","author":[{"given":"Massimo","family":"Puoti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Rossotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanna","family":"Travi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Panzeri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Morreale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erika","family":"Chiari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgia","family":"Cocca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Orso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Cristina","family":"Moioli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2013.09.001_bib0005","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1055\/s-0032-1316473","article-title":"The burden of liver disease in human immunodeficiency virus-infected patients","volume":"32","author":"Puoti","year":"2012","journal-title":"Seminars in Liver Disease"},{"key":"10.1016\/j.dld.2013.09.001_bib0010","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/hep.25941","article-title":"Human immunodeficiency virus and hepatitis C virus coinfection: the agenda is full while waiting for new drugs","volume":"57","author":"Puoti","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2013.09.001_bib0015","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/hep.25800","article-title":"The prevalence of cirrhosis and hepatocellular carcinoma in patients with human immunodeficiency virus infection","volume":"57","author":"Ioannou","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2013.09.001_bib0020","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1097\/QAD.0b013e3283574e71","article-title":"Hepatitis C virus viremia increases the incidence of chronic kidney disease in HIV-infected patients","volume":"26","author":"Peters","year":"2012","journal-title":"AIDS"},{"key":"10.1016\/j.dld.2013.09.001_bib0025","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1002\/hep.25866","article-title":"Risk of hip fracture associated with hepatitis C virus infection and hepatitis C\/human immunodeficiency virus coinfection","volume":"56","author":"Lo Re","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2013.09.001_bib0030","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1093\/cid\/cis500","article-title":"Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and Hepatitis C virus","volume":"55","author":"Berenguer","year":"2012","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.dld.2013.09.001_bib0035","first-page":"320","article-title":"Gaps in the achievement of effectiveness of HCV treatment in national VA practice","volume":"56","author":"Kramer","year":"2012","journal-title":"Journal of Hypertension"},{"key":"10.1016\/j.dld.2013.09.001_bib0040","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1001\/jama.292.23.2839","article-title":"PEG-IFN alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial","volume":"292","author":"Carrat","year":"2004","journal-title":"Journal of the American Medical Association"},{"key":"10.1016\/j.dld.2013.09.001_bib0045","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jinf.2005.09.007","article-title":"PEG-IFN alpha-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-coinfected patients","volume":"53","author":"Voigt","year":"2006","journal-title":"Journal of infection"},{"key":"10.1016\/j.dld.2013.09.001_bib0050","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa040842","article-title":"Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients","volume":"351","author":"Torriani","year":"2004","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.dld.2013.09.001_bib0055","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1089\/aid.2007.0011","article-title":"Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial","volume":"23","author":"Nunez","year":"2007","journal-title":"AIDS Research and Human Retroviruses"},{"key":"10.1016\/j.dld.2013.09.001_bib0060","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1310\/hct1303-142","article-title":"Peginterferon alfa-2a plus ribavirin for HIV-HCV genotype 1 coinfected patients: a randomized international trial","volume":"13","author":"Rodriguez-Torres","year":"2012","journal-title":"HIV Clinical Trials"},{"key":"10.1016\/j.dld.2013.09.001_bib0065","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/hep.22598","article-title":"Randomized trial comparing PEG-IFN alpha-2b versus PEG-IFN alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients","volume":"49","author":"Laguno","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2013.09.001_bib0070","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1093\/cid\/cis500","article-title":"Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and hepatitis C virus","volume":"55","author":"Berenguer","year":"2012","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.dld.2013.09.001_bib0075","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1093\/infdis\/jis449","article-title":"Comparison of high ribavirin induction versus standard ribavirin dosing. Plus peginterferon-alpha for the treatment of chronic hepatitis C in HIV-infected patients: the PERICO trial","volume":"206","author":"Labarga","year":"2012","journal-title":"Journal of Infectious Diseases"},{"key":"10.1016\/j.dld.2013.09.001_bib0080","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1097\/QAD.0b013e3281084e4d","article-title":"Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV\u2013HIV international panel","volume":"21","author":"Soriano","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.dld.2013.09.001_bib0085","series-title":"Conference on Retroviruses and Other Opportunistic Infections","article-title":"Telaprevir in combination with PEG-IFN-a-2a+ribavirin in HCV\/HIV-co-infected patients: a 24-week treatment interim analysis","author":"Dieterich","year":"2012"},{"key":"10.1016\/j.dld.2013.09.001_bib0090","series-title":"Conference on Retroviruses and Other Opportunistic Infections","article-title":"Boceprevir+PEG-IFN+ribavirin for the treatment of HCV\/HIV-coinfected patients: end of treatment (week 48) interim results","author":"Sulkowski","year":"2012"},{"key":"10.1016\/j.dld.2013.09.001_bib0095","series-title":"Conference on Retroviruses and Other Opportunistic Infections","article-title":"High early virological response with Telaprevir-pegylated-interferon-ribavirin in treatment-experienced hepatitis C virus genotype 1\/HIV co-infected patients: ANRS HC26 TelapreVIH Study","author":"Cotte","year":"2013"},{"key":"10.1016\/j.dld.2013.09.001_bib0100","series-title":"Conference on Retroviruses and Other Opportunistic Infections","article-title":"ANRS-HC27 BocepreVIH interim analysis: high early virological response with Boceprevir+PEG-IFN+ribivirin in hepatitis C virus\/HIV co-infected patients with previous failure to PEG-IFN + Ribivirin","author":"Poizot-Martin","year":"2013"},{"key":"10.1016\/j.dld.2013.09.001_bib0105","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","article-title":"Telaprevir for retreatment of HCV infection","volume":"364","author":"Zeuzem","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.dld.2013.09.001_bib0110","series-title":"EASL 48th Annual Meeting","article-title":"SVR12 rates and safety of triple therapy including Telaprevir or Boceprevir in 485 cirrhotic non responders treated in the French Early Access Program (ANRS CO20-CUPIC)","author":"Fontaine","year":"2013"},{"key":"10.1016\/j.dld.2013.09.001_bib0115","series-title":"Conference on Retroviruses and Other Opportunistic Infections","article-title":"On-treatment responses to Telaprevir-based hepatitis C treatment are similar in HIV\/hepatitis C virus co-infected and hepatitis C virus mono-infected patients","author":"Martel-Laferriere","year":"2013"},{"key":"10.1016\/j.dld.2013.09.001_bib0120","series-title":"Conference on Retroviruses and Other Opportunistic Infections","article-title":"Risk of anemia in HIV\/hepatitis C virus co-infected patients treated with Telaprevir-based hepatitis C virus therapy","author":"Kostman","year":"2013"},{"key":"10.1016\/j.dld.2013.09.001_bib0125","series-title":"Conference on Retroviruses and Other Opportunistic Infections","article-title":"Telaprevir for acute hepatitis C virus in HIV+ men both shortens treatment and improves outcome","author":"Fierer","year":"2013"},{"key":"10.1016\/j.dld.2013.09.001_bib0130","doi-asserted-by":"crossref","DOI":"10.3851\/IMP2614","article-title":"Triple combination therapy for hepatitis C with Telaprevir exhibits greater early antiviral activity than with Boceprevir","author":"Benito","year":"2013","journal-title":"Antiviral Therapy"},{"key":"10.1016\/j.dld.2013.09.001_bib0135","first-page":"792","article-title":"Clinical management of drug\u2013drug interactions in HCV therapy: challenges and solutions","volume":"58","author":"Burger","year":"2012","journal-title":"Journal of Hypertension"},{"key":"10.1016\/j.dld.2013.09.001_bib0140","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S1665-2681(19)31022-1","article-title":"A review of drug interactions with Boceprevir and Telaprevir: implications for HIV and transplant patients","volume":"11","author":"Wilby","year":"2012","journal-title":"Annals of Hepatology"},{"key":"10.1016\/j.dld.2013.09.001_bib0145","series-title":"Conference on Retroviruses and Other Opportunistic Infections","article-title":"Absence of a significant pharmacokinetic interaction between the hepatitis C virus protease inhibitor Boceprevir and HIV-1 NNRTI rilpivirine","author":"Rhee","year":"2013"},{"issue":"Suppl. 2","key":"10.1016\/j.dld.2013.09.001_bib0150","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1186\/1471-2334-12-S2-S7","article-title":"Top topics in HCV research arena","volume":"12","author":"Puoti","year":"2012","journal-title":"BMC Infectious Diseases"},{"key":"10.1016\/j.dld.2013.09.001_bib0155","series-title":"Conference on Retroviruses and Other Opportunistic Infections","article-title":"Simeprevir with PEG-IFN\/ribavirin in patients co-infected with chronic hepatitis C Virus and HIV-1: week-24 interim analysis of the TMC435-C212 study","author":"Dieterich","year":"2013"},{"key":"10.1016\/j.dld.2013.09.001_bib0160","series-title":"Conference on Retroviruses and Other Opportunistic Infections","article-title":"STARTVerso 4: high rates of early virological response in hepatitis C virus genotype 1\/HIV co-infected patients treated with faldaprevir + PEG-IFN and ribavirin","author":"Dieterich","year":"2013"},{"key":"10.1016\/j.dld.2013.09.001_bib0165","series-title":"52nd ICAAC interscience conference on antimicrobial agents and chemotherapy","article-title":"HIV\/HCV coinfected and HCV monoinfected patients have similar early hepatitis C viral kinetics with the potent HCV nucleotide polymerase inhibitor sofosbuvir (SOF)","author":"Rodriguez-Torres","year":"2012"},{"key":"10.1016\/j.dld.2013.09.001_bib0170","unstructured":"Pilot study to assess the efficacy of and tolerance to a quadruple therapy to treat HIV\u2013HCV coinfected patients previously null responders (QUADRIH). http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01725542?term=asunaprevir+daclatasvir+hiv&rank=1 (Last visit 08.05.13); 2013."},{"key":"10.1016\/j.dld.2013.09.001_bib0175","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.3748\/wjg.v18.i12.1339","article-title":"Chronic hepatitis C: treat or wait? Medical decision making in clinical practice","volume":"18","author":"Niederau","year":"2012","journal-title":"World Journal of Gastroenterology"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865813005306?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865813005306?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,27]],"date-time":"2019-07-27T07:47:03Z","timestamp":1564213623000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865813005306"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":35,"alternative-id":["S1590865813005306"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2013.09.001","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimizing treatment in HIV\/HCV coinfection","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2013.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}